Czechia presents plan for Ukraine's and Moldova's integration into EU's internal market
On Tuesday, 28 January, Czech Minister for European Affairs Martin Dvořák presented a plan for Ukraine's and Moldova's integration into the EU's internal market to his European colleagues.
Source: ČTK news agency, as reported by European Pravda
Details: Dvořák said that the plan focuses on specific proposals to deepen EU cooperation with Ukraine and Moldova, in particular in energy, telecommunications, environment and agriculture.
Quote: "I presented the Czech initiative to help Moldova and Ukraine integrate into the internal market faster. We believe this is an important step that can speed up the whole process," the Czech minister explained.
He added that so far, the Czechs have managed to enlist the support of nine other EU countries: Estonia, Finland, Germany, Romania, Latvia, Slovenia, Sweden and Denmark.
The document, quoted by ČTK, states that further economic integration into the EU through free trade agreements would significantly support Moldova and Ukraine "in their efforts to counteract the pernicious Russian influence".
Dvořák said that the acceleration of integration would be based on "our technical assistance, closer cooperation, creation of working groups and establishing contacts".
Background:
The preparation of the plan and its presentation at the EU level became known last week.
Meanwhile, according to media reports, the European Commission is allegedly considering not extending the preferential trade regime for Ukraine in its current form and has already started technical negotiations on new trade terms.
Support UP or become our patron!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Europe Mulls Speeding Up Trade Retaliation Against the US
Welcome to the Brussels Edition, Bloomberg's daily briefing on what matters most in the heart of the European Union. The EU is signaling it may accelerate retaliatory measures against the US if President Donald Trump follows through on his tariff threats, including a new 50% levy on steel and aluminum imports. The Commission said the tariff hike — from an originally planned 25% — is jeopardizing ongoing efforts to reach an agreement. A commission spokesperson said yesterday that if no solution is reached, both existing and potentially additional EU counter-measures will kick in on July 14 — or even before if the need arises. The EU's trade czar Maros Sefcovic will meet with US Trade Representative Jamieson Greer tomorrow in Paris.
Business Insider
an hour ago
- Business Insider
Europe might be increasing its defense spending, but it's moving way too slowly to be ready for Russia, says Saab CEO
Saab's CEO Micael Johansson said that while Europe's leaders have announced huge defense spending hikes, the continent's processes are likely too slow to combat Russia. "Now, we want to spend like 3.5% to 5% of GDP on defense. But then, when you start getting into the normal processes in terms of, okay, defense forces have to decide what to spend the money on, and then it has to be acquired by someone," Johansson told Business Insider on the sidelines of the Shangri-La Dialogue. "The process is much too long still. It takes a long time before it gets into industry," he said, adding that he was worried about the gap. As an example, Johansson said Sweden's recent boost in defense spending to 3.5% of GDP would take military authorities "six months roughly" to decide what to spend the funds on. And that's before acquisition and matériel officials come into the mix, he said. "And so we're still looking at a couple of years before you actually get going, which is not good enough, I think, in times of war. Which is tragic," Johansson said, who was elected president of the Aerospace, Security and Defence Industries Association of Europe last month. At the same time, the CEO raised concerns about Russia's warfooting manufacturing capability, estimating that Moscow was making up about five times as many artillery shells as all of Europe yearly. "Europe has to take its own responsibility, so we need to have integrated our missile defense systems, the collaborative combat aircraft, we need to have space technology, we need to have hubs where we can do ammunition manufacturing," he said. At the Dialogue, which ran from Friday to Sunday, Germany's defense chief Gen. Carsten Breuer raised a similar issue for his country. "I think in Germany we are a facing a situation, or at least we faced a situation, where we had processes over processes and processes, and all those processes were developed not to spend any money," Breuer said at a panel on Saturday. "Because we had enough time, but we did not have the money." Breuer said that if German officials deemed a process was moving too quickly, they would "then develop an additional process to slow it down." European military officials have warned that their nations must be ready for a possible conflict with Russia by 2029, when they estimate that Moscow would be strong enough to launch an attack on the Baltic states. Anxieties on the continent have been compounded by the second Trump administration's signaled reluctance to continue supporting regional defense in areas where European states are falling short. President Donald Trump has called for NATO's European members to boost defense spending to 5% of their GDP. Some, such as Germany, have signaled an openness to such an eventual arrangement. Saab, which manufactures the Gripen fighter jet that's geared toward fighting Russian threats, has seen a rapid surge in demand since the war in Ukraine began in 2022. The Nordics' biggest defense manufacturer reported 2024 annual sales of 63.75 billion Swedish krona, or about $6.6 billion. By comparison, annual revenue in 2021 was 39.15 billion krona.
Yahoo
an hour ago
- Yahoo
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseases Under regulatory review in the US, the EU, and China in immune thrombocytopenia Paris, June 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlusive crises, which may occur via inflammation, in sickle cell disease. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. Global Head of Development, Rare Diseases'Receiving our fourth orphan drug designation for rilzabrutinib reinforces our continued dedication to developing medicines to address the unmet medical needs of people living with rare diseases. People with sickle cell disease often live with severe episodes of pain from vaso-occlusive crises and other complications that can significantly impact both quality of life and life expectancy. There remains a need for novel treatment approaches to address these experiences by modulating the immune system responses that can contribute to sickle cell disease pathogenesis.' In addition to sickle cell disease, rilzabrutinib has received orphan drug designation for immune thrombocytopenia (ITP) in the US, the EU, and Japan, for warm autoimmune hemolytic anemia (wAIHA) in the US and the EU, and for IgG4-related disease (IgG4-RD) in the US. The safety and efficacy of rilzabrutinib have not been determined by any regulatory authority. Rilzabrutinib is currently under regulatory review in the US, the EU, and in China for its potential use in ITP. The target action date for the FDA regulatory decision for ITP, which was granted fast track designation, is August 29, 2025. Sickle cell disease supporting dataPreclinical data on sickle cell disease was presented at ASH 2024 showing that rilzabrutinib helped reduce vaso-occlusion –blockage of blood vessels – and inflammation in transgenic mice with sickle cell disease. About rilzabrutinib Rilzabrutinib is a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that has the potential to be an effective new medicine for several rare immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune modulation. BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and inflammatory pathways. With the application of Sanofi's TAILORED COVALENCY® technology, rilzabrutinib can selectively inhibit the BTK target while potentially reducing the risk of off-target side effects. About sickle cell diseaseSickle cell disease is a group of rare, genetic blood disorders in which red blood cells are misshapen, typically in a sickle or crescent shape, causing them to get stuck in small blood vessels, blocking blood flow. This can lead to episodes of severe pain as well as other health complications including infections, stroke, lung, eye, and kidney disease. Sickle cell disease affects more than 100,000 people in the US, approximately 90% of whom are African American and 3-9% of whom are Hispanic or Latino. Approximately 1 in 365 babies of African American descent born in the US have sickle cell disease, while an estimated 1 in 13 are carriers of the disease. People in the US with sickle cell disease have an estimated life expectancy that is 20 years shorter than average. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Sanofi forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release
